Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Recruiting · NCT05462574 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
No Intervention
What this trial is about
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- ≥ 18 years old
- Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations.
- Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted.
- WHO Functional Class I-III
- Ambulatory
- Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test
Exclusion criteria
- Pregnancy
- Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins
- WHO Functional class IV heart failure
- Requirement for continuous oxygen
- Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test.
- Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI
Where it is running
1 location listed across 1 US state.
- Vanderbilt University Medical Center - Nashville, Tennessee, United States